How have ATNF shares performed in 2024?

180 Life Sciences' stock was trading at $4.0565 at the beginning of 2024. Since then, ATNF shares have decreased by 55.1% and is now trading at $1.8201. View the best growth stocks for 2024 here .

Are investors shorting 180 Life Sciences?

180 Life Sciences saw a decrease in short interest in March. As of March 31st, there was short interest totaling 42,400 shares, a decrease of 31.4% from the March 15th total of 61,800 shares. Based on an average trading volume of 96,000 shares, the short-interest ratio is currently 0.4 days. Currently, 8.4% of the company's shares are sold short. View 180 Life Sciences' Short Interest .

When is 180 Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ATNF earnings forecast .

When did 180 Life Sciences' stock split?

180 Life Sciences's stock reverse split on the morning of Wednesday, February 28th 2024. The 1-19 reverse split was announced on Wednesday, February 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of 180 Life Sciences?

Shares of ATNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ATNF

180 Life Sciences (ATNF) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free ATNF Stock Alerts

$1.82

-0.01 (-0.55%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.80
▼
$1.94
50-Day Range: $1.48
▼
$4.15
52-Week Range: $1.33
▼
$27.93

Volume: 19,839 shs
Average Volume: 110,659 shs
Market Capitalization: $1.55 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get 180 Life Sciences alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About 180 Life Sciences Stock (NASDAQ:ATNF)

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

ATNF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATNF Stock News Headlines

March 14, 2024 | finanznachrichten.de

180 Life Sciences Corp.: 180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

March 14, 2024 | finance.yahoo.com

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 14, 2024 | globenewswire.com

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

February 26, 2024 | markets.businessinsider.com

180 Life Sciences Announces 1-For 19 Reverse Stock Split - Quick Facts

February 26, 2024 | globenewswire.com

180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan

February 17, 2024 | thestreet.com

180 Life Sciences Corp.

December 20, 2023 | benzinga.com

180 Life Sciences Stock (NASDAQ:ATNF), Quotes and News Summary

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

December 4, 2023 | marketwatch.com

180 Life Sciences Hires Financial Adviser to Help Explore Strategic Alternatives

December 4, 2023 | finance.yahoo.com

180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives

November 28, 2023 | finanznachrichten.de

180 Life Sciences Corp.: 180 Life Sciences Announces Review of Strategic Alternatives

November 28, 2023 | finance.yahoo.com

180 Life Sciences Announces Review of Strategic Alternatives

October 7, 2023 | nasdaq.com

180 Life Sciences Corp. Common Stock (ATNF)

September 15, 2023 | benzinga.com

Innovative Biotech Company Announces Agreement To Perform CBD Pill Clinical Study

August 14, 2023 | finance.yahoo.com

180 Life Sciences Corp. Announces Closing of $3 Million Public Offering

August 7, 2023 | benzinga.com

180 Life Sciences Teams Up With Hadassah Hospital To Test A New Formulation Of CBD For Enhanced Oral Uptake

August 7, 2023 | finance.yahoo.com

180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake

August 3, 2023 | finance.yahoo.com

180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren’s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA

July 31, 2023 | benzinga.com

180 Life Sciences Files A Provisional Patent For CBD-Based Appetite Suppressant

July 31, 2023 | finance.yahoo.com

180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite

April 10, 2023 | finance.yahoo.com

180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement

April 5, 2023 | finance.yahoo.com

180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement

April 5, 2023 | investorplace.com

Why Is 180 Life Sciences (ATNF) Stock Up 30% Today?

February 28, 2023 | finance.yahoo.com

180 Life Sciences Announces Presentation at the Gordon Conference

February 27, 2023 | finance.yahoo.com

180 Life Sciences Announces Presentation at the Gordon Conference

February 23, 2023 | finance.yahoo.com

180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and Application

See More Headlines

Receive ATNF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 180 Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ATNF
CUSIP: N/A
CIK: 1690080
Web: www.kblmerger.com
Phone: (650) 507-0669
Fax: N/A
Employees: 5
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,930,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -320.26%
Return on Assets: -112.07%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.72
Quick Ratio: 0.72

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.24) per share
Price / Book: -8.03

Miscellaneous

Outstanding Shares: 850,000
Free Float: 818,000
Market Cap: $1.64 million
Optionable: No Data
Beta: 0.44

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Dr. Lawrence Steinman BA (Age 76)
M.D., Ph.D., Co-Founder & Executive Chairman
Comp: $168.75k
Dr. James N. Woody M.D. (Age 82)
Ph.D., CEO & Director
Comp: $617.77k
Mr. Ozan Pamir C.F.A. (Age 32)
CFO & Secretary
Comp: $410.24k
Dr. Jonathan B. Rothbard Ph.D. (Age 71)
Chief Scientific Officer
Comp: $260.34k
Prof. Jagdeep Nanchahal
Co-Founder & Chairman of Clinical Advisory Board
Mr. Jason Assad
Director of IR

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ATNF Stock Analysis - Frequently Asked Questions

How have ATNF shares performed in 2024?: 180 Life Sciences' stock was trading at $4.0565 at the beginning of 2024. Since then, ATNF shares have decreased by 55.1% and is now trading at $1.8201.
View the best growth stocks for 2024 here.
Are investors shorting 180 Life Sciences?: 180 Life Sciences saw a decrease in short interest in March. As of March 31st, there was short interest totaling 42,400 shares, a decrease of 31.4% from the March 15th total of 61,800 shares. Based on an average trading volume of 96,000 shares, the short-interest ratio is currently 0.4 days. Currently, 8.4% of the company's shares are sold short.
View 180 Life Sciences' Short Interest.
When is 180 Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ATNF earnings forecast.

When did 180 Life Sciences' stock split?: 180 Life Sciences's stock reverse split on the morning of Wednesday, February 28th 2024. The 1-19 reverse split was announced on Wednesday, February 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
How do I buy shares of 180 Life Sciences?: Shares of ATNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATNF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial